The Efficacy of Interferon-Alpha Treatment in Human T-Lymphotropic Virus Type-I-Associated Myelopathy

17Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

We investigated the efficacy of interferon-alpha (IFN-α) treatment in 5 patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM). Treatment with IFN-α yielded clinical improvement of gait, and sensory and/or sphincter disturbance in 4 out of the 5 HAM patients. IFN- α treatment did not bring about uniform changes in lymphocyte subsets or anti-HTLV-I antibody titer of peripheral blood. Although the stimulation indexes to phytohemagglutinin, concanavalin A, and pokeweed mitogen were decreased in the culture of the peripheral blood lymphocytes (PBL) in the 5 HAM patients before the treatment, the stimulation indexes to these mitogens were significantly increased except in 1 case after the IFN- α treatment. These changes were based primarily on the depression of the spontaneous proliferation of PBL without mitogen. These results appear to point out a very important phenomenon for the investigation of the pathogenesis of HAM. © 1990, The Japanese Society of Internal Medicine. All rights reserved.

Cite

CITATION STYLE

APA

Nakamura, T., Shibayama, K., Nagasato, K., Matsuo, H., Tsujihata, M., & Nagataki, S. (1990). The Efficacy of Interferon-Alpha Treatment in Human T-Lymphotropic Virus Type-I-Associated Myelopathy. Japanese Journal of Medicine, 29(4), 362–367. https://doi.org/10.2169/internalmedicine1962.29.362

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free